[1] Hu JY, Zhou HB, Liu WD,et al.A comparative study of intrahepatic cholangiocarcinoma and hepatocellular carcinoma with reference to clinical features and prognosis. Chin J Hepatol, 2019, 27:511-515. [2] Bertuccio P, Malvezzi M, Carioli G,et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocar-cinoma. J Hepatol, 2019, 71:104-114. [3] Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol,2012, 56:848-854. [4] Bridgewater J, Galle PR, Khan SA,et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol,2014, 60:1268-1289. [5] Sahai V, Catalano PJ, Zalupski MM,et al.Nab-Paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA oncol, 2018, 4:1707-1712. [6] Chun YS, Javle M. Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma. Cancer Control, 2017, 24:1073274817729241. [7] Kim JH, Yoon HK, Sung KB,et al.Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer,2008, 113:1614-1622. [8] Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer, 2015, 6:1099-1104. [9] 冯泽东, 白琪, 王博方,等.肝内胆管细胞癌治疗靶点研究进展. 中华肝脏外科手术学电子杂志, 2020, 9:92-94. [10] 董志涛, 沈伟峰.肝内胆管细胞癌治疗进展. 中华肝脏外科手术学电子杂志, 2020, 9:6-10. [11] Si A, Li J, Xiang H, et al.Actual over 10-year survival after liver resection for patients with intrahepatic cholangiocarcinoma. Oncotarget,2017, 8:44521-44532. [12] Chen W, Wu Z, Cao L.Hepatectomy is associated with survival in intrahepatic cholangiocarcinoma: an observational study by instrumental variable analysis. Medicine, 2021, 100:e24147. [13] Chan KM, Tsai CY, YEH CN.Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence. BMC Gastroenterol,2018, 18:180. [14] Kang CM, Suh KS, Yi NJ, et al.Should lymph nodes be retrieved in patients with intrahepatic cholangiocarcinoma? A Collaborative Korea-Japan Study. Cancers,2021, 13. [15] Chang ME, Lei HJ, Chen MH. Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center.J CHIN MED ASSO, 2017, 80. [16] Asaoka T, Kobayashi S, Hanaki T, et al.Clinical significance of preoperative CA19-9 and lymph node metastasis in intrahepatic cholangiocarcinoma. Surg Today,2020, 50:1176-1186. [17] Bagante F, Spolverato G, Weiss M, et al. Assessment of the lymph node status in patients undergoing liver resection for intrahepatic cholangiocarcinoma: the new eighth edition AJCC staging system. J Gastrointest Surg,2018, 22:52-59. [18] Kim SH, Han DH, Choi GH. Recommended Minimal Number of Harvested Lymph Nodes for Intrahepatic Cholangiocarcinoma. J Gastrointest Surg, 2020. [19] Rafecas A, Torras J, Fabregat J,et al. Prognostic factors for recurrence and survival in a series of 67 patients treated surgically at a single center. Cir. Espan. 2020. S0009-739X(20)30234-7 [20] Tsukamoto M, Yamashita YI, Imai K, et al. Predictors of cure of intrahepatic cholangiocarcinoma after hepatic resection. Anticancer Res, 2017, 37:6971-6975. [21] Hu LS, Weiss M, Popescu I, et al. Impact of microvascular invasion on clinical outcomes after curative-intent resection for intrahepatic cholangiocarcinoma. J Surg Oncol, 2019, 119:21-29. [22] Chen C, Wu YH, Zhang JW, et al. A prognostic model of intrahepatic cholangiocarcinoma after curative intent resection based on Bayesian network. Zhonghua Wai Ke Za Zhi,2021, 59:265-271. [23] Yu TH, Chen X, Zhang XH,et al. Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study. Sci Rep,2021, 11:3990. |